Eisenberg S. Refractory response to platelet transfusion therapy. J Infus Nurs. 2010;33:89–97.

Article  PubMed  Google Scholar 

Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol. 2008;142:348–60.

Article  PubMed  Google Scholar 

Stanworth SJ, Navarrete C, Estcourt L, Marsh J. Platelet refractoriness–practical approaches and ongoing dilemmas in patient management. Br J Haematol. 2015;171:297–305.

Article  PubMed  Google Scholar 

Kerkhoffs JL, Eikenboom JC, van de Watering LM, van Wordragen-Vlaswinkel RJ, Wijermans PW, Brand A. The clinical impact of platelet refractoriness: correlation with bleeding and survival. Transfusion. 2008;48:1959–65.

Article  PubMed  Google Scholar 

Toor AA, Choo SY, Little JA. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation. Bone Marrow Transpl. 2000;26:315–20.

Article  CAS  Google Scholar 

Comont T, Tavitian S, Bardiaux L, Fort M, Debiol B, Morère D, et al. Platelet transfusion refractoriness in patients with acute myeloid leukemia treated by intensive chemotherapy. Leuk Res. 2017;61:62–7.

Article  PubMed  Google Scholar 

Meehan KR, Matias CO, Rathore SS, Sandler SG, Kallich J, LaBrecque J, et al. Platelet transfusions: utilization and associated costs in a tertiary care hospital. Am J Hematol. 2000;64:251–6.

Article  CAS  PubMed  Google Scholar 

Bishop JF, McGrath K, Wolf MM, Matthews JP, De Luise T, Holdsworth R, et al. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood. 1988;71:383–7.

Article  CAS  PubMed  Google Scholar 

Murphy MF, Waters AH. Platelet transfusions: the problem of refractoriness. Blood Rev. 1990;4:16–24.

Article  CAS  PubMed  Google Scholar 

Doughty HA, Murphy MF, Metcalfe P, Rohatiner AZ, Lister TA, Waters AH. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang. 1994;66:200–5.

CAS  PubMed  Google Scholar 

Gouttefangeas C, Diehl M, Keilholz W, Hörnlein RF, Stevanović S, Rammensee HG, et al. molecules retain nonrenewable endogenous peptides of megakaryocyte lineage and do not stimulate direct allocytotoxicity in vitro. Blood. 2000;95:3168–75.

Article  CAS  PubMed  Google Scholar 

Forest SK, Hod EA. Management of the Platelet Refractory Patient. Hematol Oncol Clin North Am. 2016;30:665–77.

Article  PubMed  Google Scholar 

Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969;280:735–9.

Article  CAS  PubMed  Google Scholar 

Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320:197–204.

Article  CAS  PubMed  Google Scholar 

Mattsson J, Ringdén O, Storb R. Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2008;14:165–70.

Article  Google Scholar 

Süsal C, Opelz G. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation. 2002;73:1269–73.

Article  PubMed  Google Scholar 

Ciurea SO, de Lima M, Cano P, Korbling M, Giralt S, Shpall EJ, et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation. 2009;88:1019–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Youk HJ, Hwang SH, Oh HB, Ko DH. Evaluation and management of platelet transfusion refractoriness. Blood Res. 2022;57:6–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rioux-Massé B, Cohn C, Lindgren B, Pulkrabek S, McCullough J. Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion. Transfusion. 2014;54:3080–7.

Article  PubMed  Google Scholar 

Pons-Estel GJ, Salerni GE, Serrano RM, Gomez-Puerta JA, Plasin MA, Aldasoro E, et al. Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature. Autoimmun Rev. 2011;10:679–84.

Article  PubMed  Google Scholar 

Weinstein R. Basic principles of therapeutic blood exchange. In: McLeod BC, Weinstein R, Winters JL, Szczepiorkowski ZM, editors. Apheresis: principles and practice. 3rd ed. Bethesda: AABB Press; 2010. pp. 269–94.

Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019;34:171–354.

Xu L, Chen H, Chen J, Han M, Huang H, Lai Y, et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J Hematol Oncol. 2018;11:33.

Article  PubMed  PubMed Central  Google Scholar 

Rebulla P, Morelati F, Revelli N, Villa MA, Paccapelo C, Nocco A, et al. Outcomes of an automated procedure for the selection of effective platelets for patients refractory to random donors based on cross-matching locally available platelet products. Br J Haematol. 2004;125:83–9.

Article  PubMed  Google Scholar 

Sareban N, Macher S, Drexler C, Posch U, Lanzer G, Schallmoser K. Platelet antibody analysis by three different tests. J Clin Lab Anal. 2015;29:198–202.

Article  CAS  PubMed  Google Scholar 

Takanashi M, Atsuta Y, Fujiwara K, Kodo H, Kai S, Sato H, et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood. 2010;116:2839–46.

Article  CAS  PubMed  Google Scholar 

Pavenski K, Rebulla P, Duquesnoy R, Saw CL, Slichter SJ, Tanael S, et al. International Collaboration for Guideline Development, Implementation and Evaluation for Transfusion Therapies (ICTMG) Collaborators. Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review. Transfusion. 2013;53:2230–42.

Article  CAS  PubMed  Google Scholar 

Kongtim P, Cao K, Ciurea SO. Donor specific anti-HLA antibody and risk of graft failure in haploidentical stem cell transplantation. Adv Hematol. 2016;2016:4025073.

Article  PubMed  PubMed Central  Google Scholar 

Bearden CM, Agarwal A, Book BK, Vieira CA, Sidner RA, Ochs HD, et al. Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am J Transplant. 2005;5:50–7.

Article  CAS  PubMed  Google Scholar 

Vo P, Purev E, West KA, McDuffee E, Worthy T, Cook L, et al. A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients. Br J Haematol. 2020;189:551–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang YJ, Xu LP, Wang Y, Zhang XH, Chen H, Chen YH, et al. Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody. Bone Marrow Transpl. 2020;55:1326–36.

Article  CAS  Google Scholar 

Bailén R, Vicario JL, Solán L, Sánchez-Vadillo I, Herrera P, Calbacho M, et al. Management of donor-specific antibodies in haploidentical transplant: multicenter experience from the Madrid group of hematopoietic transplant. Front Immunol. 2021;12:674658.

Article  PubMed  PubMed Central  Google Scholar 

Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the seventh special issue. J Clin Apher. 2016;31:149–62.

PubMed  Google Scholar 

Ciurea SO, Cao K, Fernandez-Vina M, Kongtim P, Malki MA, Fuchs E, et al. The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transpl. 2018;53:521–34.

Article  CAS